Ergot Alkaloid Pharmacology

Ergotamine produces its antimigraine effect primarily through agonist activity at serotonin type 1B and serotonin type 1D receptors located on the walls of meningeal blood vessels and on trigeminal nerve terminals. Activation of serotonin type 1B receptors on meningeal vessel walls causes vasoconstriction, reducing the abnormal dilation of these vessels that contributes to migraine pain. Activation of serotonin type 1D receptors on trigeminal nerve terminals inhibits the release of inflammatory neuropeptides — particularly calcitonin gene-related peptide — that drive neurogenic inflammation in the meninges.

This is the same dual mechanism used by the triptans. The critical difference is selectivity. Triptans are highly selective for serotonin type 1B and 1D receptors. Ergotamine also binds serotonin type 2 receptors, alpha-adrenergic receptors, and dopamine receptors simultaneously. This broader receptor engagement is the source of most of ergotamine's adverse effects and contraindications.

Ergotamine is available for oral, sublingual, and rectal administration. Oral bioavailability is highly variable and generally low due to extensive first-pass hepatic metabolism — a patient may absorb very little of an oral dose on one occasion and a substantially larger fraction on another. Rectal administration bypasses first-pass metabolism and provides more consistent absorption, which is why the rectal formulation is used when rapid, reliable drug delivery is needed in a patient with severe nausea who cannot take oral medication.

The sublingual route offers faster onset than oral administration but still suffers from significant variability. In clinical practice, the combination tablet formulation — ergotamine tartrate with caffeine, available as Cafergot — is the most commonly used oral preparation. Caffeine serves two purposes in this combination: it enhances ergotamine absorption from the gastrointestinal tract and may contribute independently to vasoconstriction.

Triptans displaced ergotamine as the preferred acute migraine treatment because they are more selective, more predictable in their effects, and better tolerated. The non-selectivity of ergotamine means that a patient taking it for a migraine is also receiving alpha-adrenergic stimulation, serotonin type 2 receptor stimulation, and dopaminergic stimulation throughout the body — producing peripheral vasoconstriction, nausea, and other effects that triptans largely avoid.

Ergotamine retains a clinical role primarily for patients with prolonged migraine attacks lasting more than 48 hours, where its longer duration of pharmacodynamic effect compared to triptans may be an advantage, and for patients who have failed triptan therapy. For most patients with acute migraine, triptans are the preferred specific therapy.

Coronary artery disease is an absolute contraindication to both ergotamine and dihydroergotamine. Vasospasm of the coronary arteries from alpha-adrenergic and serotonin type 2 receptor activation can precipitate myocardial ischemia or infarction in a patient with already-compromised coronary blood flow. Peripheral vascular disease is contraindicated for the same reason — ergot-induced vasoconstriction reduces blood flow in vessels that are already narrowed.

Uncontrolled hypertension is a contraindication because ergot-induced systemic vasoconstriction raises blood pressure further. Pregnancy is an absolute contraindication because the uterotonic activity of ergotamine can induce uterine contractions and threaten the pregnancy — the same mechanism that makes methylergonovine useful in obstetrics is dangerous in a pregnant migraine patient.

Ergot alkaloids and triptans must not be used within 24 hours of each other. Both drug classes constrict meningeal blood vessels through serotonin type 1B receptor agonism, and combining them within the same 24-hour period risks additive vasoconstriction that can extend to coronary and peripheral arteries. This additive vasospasm has caused myocardial infarction and stroke in patients who received both within a short interval.

The 24-hour rule applies in both directions: a patient who has taken ergotamine must wait 24 hours before taking a triptan, and a patient who has taken a triptan must wait 24 hours before taking ergotamine. This interval is based on the prolonged pharmacodynamic effect of ergotamine, which persists well beyond its plasma half-life due to tight receptor binding in vascular smooth muscle.

Frequent use of ergotamine — generally defined as use on ten or more days per month — leads to medication overuse headache, also called rebound headache. The mechanism involves changes in central pain processing that result from repeated exposure to acute antimigraine medication. As the drug wears off, headache returns and the patient takes another dose, creating a cycle of increasing medication use and worsening baseline headache frequency.

Ergotamine has a higher risk of producing medication overuse headache than triptans, likely because of its longer duration of pharmacodynamic effect and its broader receptor activity. Management requires withdrawal of the overused medication, which initially worsens headache before it improves. Recognizing medication overuse headache as a complication of frequent ergotamine use — and distinguishing it from treatment-refractory migraine — is an important clinical concept at the second-year level.